Maxcyte annual operating margin
2019
2020
2021
2022
2023
2024
2025
Maxcyte Operating Margin Growth & History (MXCT)
Maxcyte's operating margin was −247.64% for fiscal 2025.
View full Maxcyte company overviewMaxcyte annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −247.64% | −17.17 pp |
| 2024 | 2024-12-31 | −230.46% | +17.26 pp |
| 2023 | 2023-12-31 | −247.73% | −152.55 pp |
| 2022 | 2022-12-31 | −95.18% | −10.86 pp |
| 2021 | 2021-12-31 | −84.32% | −12.76 pp |
| 2020 | 2020-12-31 | −71.56% | +22.13 pp |
| 2019 | 2019-12-31 | −93.68% | — |
Maxcyte quarterly operating margin
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −207.29% | +36.99 pp |
| Q1 2026 | 2026-03-31 | −137.41% | +76.67 pp |
| Q4 2025 | 2025-12-31 | −234.51% | −21.41 pp |
| Q3 2025 | 2025-09-30 | −307.39% | −56.98 pp |
| Q2 2025 | 2025-06-30 | −244.28% | −3.23 pp |
| Q1 2025 | 2025-03-31 | −214.09% | +5.74 pp |
| Q4 2024 | 2024-12-31 | −213.10% | −42.84 pp |
| Q3 2024 | 2024-09-30 | −250.41% | +85.30 pp |
| Q2 2024 | 2024-06-30 | −241.05% | −8.51 pp |
| Q1 2024 | 2024-03-31 | −219.82% | +45.65 pp |
| Q4 2023 | 2023-12-31 | −170.26% | −83.22 pp |
| Q3 2023 | 2023-09-30 | −335.71% | −227.88 pp |
| Q2 2023 | 2023-06-30 | −232.53% | −107.37 pp |
| Q1 2023 | 2023-03-31 | −265.47% | −204.82 pp |
| Q4 2022 | 2022-12-31 | −87.04% | −21.01 pp |
| Q3 2022 | 2022-09-30 | −107.83% | −64.27 pp |
| Q2 2022 | 2022-06-30 | −125.16% | −20.45 pp |
| Q1 2022 | 2022-03-31 | −60.65% | +89.69 pp |
| Q4 2021 | 2021-12-31 | −66.03% | −5.15 pp |
| Q3 2021 | 2021-09-30 | −43.56% | +78.72 pp |
| Q2 2021 | 2021-06-30 | −104.71% | — |
| Q1 2021 | 2021-03-31 | −150.34% | — |
| Q3 2020 | 2020-09-30 | −60.87% | — |
| Q2 2020 | 2020-06-30 | −122.28% | — |
Maxcyte operating margin trends
Over the last five reported fiscal years, Maxcyte's operating margin decreased from −71.56% to −247.64%, a change of −176.08 percentage points. The latest reported quarter, Q2 2026, shows −207.29%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maxcyte filings at SEC.gov ↗